Highlights the importance of understanding pharmacokinetics, drug interactions, and side effects to optimize the benefit-to-risk ratio of antiarrhythmic therapy.
Reinforces individualized antiarrhythmic prescribing amid interaction risks; extends reviews by highlighting gaps for targeted trials.
Currently available antiarrhythmic agents are limited by side effects and the potential for increasing arrhythmias. In addition, drug interactions, altered disposition of drug as a result of changes in protein binding or concomitant disease processes, active metabolites, and poorly defined therapeutic ranges with great interpatient variability are some of the factors which complicate therapy. An awareness of the possible contribution of these factors in the use of antiarrhythmics is invaluable in both the choice of agent and the establishment of an optimum benefit-to-risk ratio for the patient.
No takes yet. Share an insight, caveat, or question.
Woosley et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: